On the Couch with Jon Pilcher: What's Next for Neuren Pharma
About this episode
Welcome to another episode of 'On the Couch'. This occasional podcast series of chats with brokers, CEOs, and fund managers aims to give you an insight into the investing world.
In this episode, Henry Jennings welcomes back Jon Pilcher, CEO of Neuren Pharma (NEU).
Jon is an old friend, having joined us around two years ago to discuss the exciting deal with Acadia for their 'Daybue' drug, developed to treat Rett Syndrome. Since then, much has changed, with even more to come.
2025 is shaping up to be another good year for NEU. Cashed up with leverage to its new drug in trials, NNZ-2591. Don't miss this opportunity to hear the NEU success story first-hand.
Disclaimer: This is general advice only and you should consult your financial adviser regarding any of the thoughts, ideas or insights in this podcast.
Why not sign up for a free trial? Get access to expert insights and research and become a better investor.
Get every episode summarized
Each time On the Couch publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from On the Couch
On the Couch with Nick Griffin (Munro Partners): Markets, AI and Global Tech The...
On the Couch
Ask the Analyst | 17 April
On the Couch
Why the Next Six Months Could Get Tough for Small Caps: On the Couch with Chris...
On the Couch
On the Couch with Coby Hanoch (Weebit Nano): The Memory Boom Behind AI
On the Couch